Chemours (CC): insider & executive buying
Chemours · Materials · ref. ETF XLB · price $15.88
In short — 7 insiders bought Chemours over ~6 months (7 buys, total $489k, latest Aug 12, 26) — cluster buy. Public Form 4 data, informative (not a performance signal).
Are Chemours's executives buying their own shares? Here are the disclosed insider buys over the last 6 months — a transparency data point, not an outperformance signal.
📈 1-year price
$15.88+5.4% over range
Aug 28, 25low $10.48 · high $27.94Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
57% recommend buying · 7 analysts
Latest insider buys on Chemours
| Date | Insider | Role | Shares | Amount |
|---|---|---|---|---|
| Aug 12, 26 | Familiar Calderon Gerardo | See Remarks | 1,935 | $30k |
| Aug 11, 26 | Dignam Denise | CEO | 3,378 | $51k |
| Aug 7, 26 | Cowan Alister | Dir | 13,000 | $203k |
| Aug 7, 26 | Foley Michael Robert | See Remarks | 1,934 | $30k |
| Aug 7, 26 | Cranston Mary B | Dir | 6,000 | $95k |
| Aug 7, 26 | Martinko Joseph T. | See Remarks | 1,940 | $30k |
| Aug 6, 26 | Hostetter Shane | CFO | 3,350 | $50k |
⚠️ Open-market buys reported to the SEC (Form 4). Transparency data, not advice nor an outperformance signal (our backtests show no reliable edge).
Frequently asked questions
Have Chemours's executives bought shares recently?
7 Chemours insider(s) bought $489k over ~6 months (latest Aug 12, 26). A buy shows confidence, but our backtests show no performance edge.
Is insider buying a good signal for CC?
It's useful transparency data, but NOT a performance guarantee: our historical tests show no reliable edge from following insider buys. Cross-check with fundamentals and analyst views.
Where does this data come from?
From Form 4 filings with the SEC (mandatory for officers and 10%+ holders), aggregated and refreshed regularly.
💬 A question about Chemours? The JPI assistant answers using our backtest data.